The Use of Intramuscular Ceftriaxone in Infants during the First Week of Life to Minimize the Risk of Late Onset Group B Strep Disease in Inadequately, Prenatally Treated Newborns

7/20/2021

Robert A. Dracker, MD, MHA, MBA, CPI

About presenter

Dr. Dracker is the medical director of Summerwood Pediatrics in Syracuse, New York. Dr. Dracker is trained in Pediatrics, Pediatric Hematology/Oncology and Blood Banking/Transfusion Medicine. He has been in private practice since 1993 and along with his staff, cares for over 20,000 children in the Central New York Area. He is currently an advisor to the Pediatric Advisory Committee of the FDA and has been a previous board member and Chairman of the committee in 2019-2020.

Ameer Ahmad

7/20/2021 09:23:15 pm

Great presentation

Dr. Robert A. Dracker

7/22/2021 08:45:34 am

Hello Ameer, thank you for watching it and I appreciate the complement. Please let me know if you have any further questions. Bob

Group B Strep International

7/20/2021 10:43:33 pm

Thank you, Dr. Dracker, for presenting for us! We are eager to learn about your strategy to minimize the risk of late-onset GBS disease.

Diana Dunsmore

7/21/2021 07:30:39 am

My presentation stops at 6:31, but did not seem to be concluded. I would love to hear more.

Bless you Dr. Dracker for going beyond with your thoughts and care. And blessed are the families you have helped! My DIL did not get a full round nor any information of what to Wait and Watch for. The outcome for the baby has been tragic. Please continue to educate your peers.

Diana Dunsmore

7/26/2021 03:25:18 am

I have now been able to see the remainder of the presentation. Thank you!
It did my heart good to hear you encourage surveillance and identification of at risk infants!!! My strong and healthy full-term grandson was sent home with no further information or cautions. Way too late I've learned about GBS, IAP and the risks of breastfeeding for a positive mom. So much wrong in that picture! So much damage to that little one- after seizures followed by 8 weeks of antibiotics. Sadly he gave us every sign but we were unaware.
Also, during my learning I have wondered if there would be a connection discovered to SIDS, and here it is. How sad.
Again, thank you for going above and beyond. I hope you are able to educate and impress your peers with the importance of this new protocol. Please keep up your work!

Ronald Librizzi, DO

7/21/2021 07:46:13 am

Thank you and my presentation also appeared to cut short abruptly after the discussion of early signs of late onset GBS disease are not always obvious or reliable. That being said, I would love to hear more about the outcome strategy for late onset disease utilizing your protocol. Great presentation.

Group B Strep International

7/21/2021 08:27:38 am

Thank you for bringing this to our attention. The presentation is now able to be viewed in its entirety. Our apologies for the technical difficulty!

Diana Dunsmore

7/26/2021 03:30:44 am

It's up and fine now. Thank you.
I can't imagine all that is involved with presenting this conference and so appreciate it!

Amelia P

7/21/2021 10:06:23 am

Very interesting observations and implications. Thank you for your work!

Dr. Robert A. Dracker

7/22/2021 08:46:35 am

Hello Amelia, thank you for your comment, please let me know if you have any further questions, Bob

James McGregor

7/21/2021 03:41:11 pm

Thank you for addressing these critically unsolved clinical conundrums! Please consider making 1)your protocol and parental consent available to other providers and policy makers.2) Please also consider publishing ( letter form?) in a Pediatric journal such as J Ped infection ( JPID), and3) please prepare a rudimentary power analysis. ( which will show how difficult preventing late onset GBS disease is, relying on clinical acumen and empirical judgment. Thank you for clarifying that this is not standard and not preferable to vaccination.

Dr. Robert A. Dracker

7/22/2021 08:48:08 am

Hello Jim, I greatly appreciate your suggestions. As you noted, I do not intend to suggest that this should be a standard of care, but it was my attempt to deal with a clinical problem which has no simple solution. Thank you, Bob

James mcgregor

7/22/2021 04:34:10 pm

Thanks again. Could you please clarify if you know of any accurate/ useful ways to clinically identify any baby with Late onset Gbs,or E. coli new born sepsis. I your preventive approach justifies a much larger controlled trial. How would you follow effects on the babies’ microbiome ? And associated changes in children’s immune health? Should your approach work for E. coli Late onset disease? Thanks again!

Marti Perhach

7/22/2021 08:07:03 am

How long might the ceftriaxone protect the baby from GBS infection from sources other than the mother?

Dr. Robert A. Dracker

7/22/2021 08:50:28 am

Generally speaking, transmission from the mother at the time of birth represents the predominant route of infection. Other sources and forms of direct exposure would be relatively inconsequential. A single IM dose of ceftriaxone however would most likely be bactericidal for 72 hours. Thank you

Louis

7/22/2021 08:28:44 am

It would be interesting to know if maternal colonization levels at birth are a factor in late-onset. You mention maternal GBS status as part of your protocol considerations. Was the presence of any GBS bacteriuria in that pregnancy considered in your review?

Dr. Robert A. Dracker

7/22/2021 08:51:28 am

No it was not considered but it is a very interesting suggestion which will be considered if a prospective study is considered. Thank you for your comment, Bob

James McGregor

7/22/2021 04:20:01 pm

Diana Dunsmore

7/26/2021 03:35:02 am

Yes, please do!!!

Comments are closed.

The Use of Intramuscular Ceftriaxone in Infants during the First Week of Life to Minimize the Risk of Late Onset Group B Strep Disease in Inadequately, Prenatally Treated Newborns

Search by theme

Join the Campaign against GBS Disease in babies!

CONNECT TO GBSI

The Use of Intramuscular Ceftriaxone in Infants during the First Week of Life to Minimize the Risk of Late Onset Group B Strep Disease in Inadequately, Prenatally Treated Newborns

Search by theme

Join the Campaign against GBS Disease in babies!

​CONNECT TO GBSI

CONNECT TO GBSI